YishengBio

YishengBio is a global biopharmaceutical company with fully integrated research, manufacturing and commercialization capabilities developing innovative biotherapeutics for cancers and infectious diseases. Leveraging our proprietary PIKA® immunomodulating technology platform, we have built a pipeline of diverse novel candidate biotherapeutics with first- and best-in-class potential. Our candidates include YS-ON-001 for the treatment of advanced solid tumors, YS-HBV-001 vaccine for hepatitis B prevention, YS-HBV-002 for chronic hepatitis B therapy and the PIKA rabies vaccine for accelerated post-exposure prophylaxis.

Developing Diverse Biotherapeutics Based on TLR3, RIG-I and MDA5 Activation

Yisheng PIKA technology consists of biologic complexes that incorporate an agonist of multiple pathways of immune signaling: TLR3, RIG-I and MDA5. When delivered with relevant protein-based molecules, PIKA technology is offering a promising platform for the development of a wide variety of novel biotherapeutics as new generation of antiviral vaccines, antiviral therapeutics and anticancer therapeutics.